$JNJ · Johnson & Johnson SEC Filings
Position Tracker tracks 10 SEC EDGAR filings for Johnson & Johnson ($JNJ) from August 14, 2026 through October 26, 2026, including 0 Form 10-K annual reports, 1 Form 10-Q quarterly earnings reports, 1 Form 8-K current event disclosures, and 7 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
$JNJ 13F-HR — Johnson & Johnson
Johnson & Johnson filed a quarterly Form 13F-HR disclosing its public equity holdings for the reporting period. The filing lists investments in a range of biotechnology and heal…
$JNJ 10-Q — Johnson & Johnson
Johnson & Johnson filed its quarterly report on Form 10-Q for the fiscal quarter ended September 27, 2026. The filing covers the three and nine months ended September 27, 2026,…
$JNJ 8-K — Johnson & Johnson
On October 13, 2026, Johnson & Johnson filed a current report on Form 8-K with the Securities and Exchange Commission announcing its financial results for the third quarter ende…
$JNJ 4 — Johnson & Johnson
Johnson & Johnson filed a Form 4 reporting a change in beneficial ownership for Daniel E. Pinto, a director of the company. The filing states that on September 8, 2026, Mr. Pint…
$JNJ 4 — Johnson & Johnson
This filing is a Form 4 statement of changes in beneficial ownership submitted by Eugene A. Woods, a director of Johnson & Johnson. It reports a transaction dated September 8, 2…
$JNJ 4 — Johnson & Johnson
Johnson & Johnson filed a Form 4 reporting a change in beneficial ownership for Marillyn A. Hewson, a director of the company. On September 8, 2026, Hewson acquired 180.956 Defe…
$JNJ 4 — Johnson & Johnson
This Form 4 reports transactions by Timothy Schmid, an executive vice president and worldwide chair of MedTech at Johnson & Johnson. On September 2, 2026, he exercised two emplo…
$JNJ 3 — Johnson & Johnson
Johnson & Johnson filed a Form 3 initial statement of beneficial ownership for Thomas Cavanaugh, who is identified as Executive Vice President, Worldwide Chair, Innovative Medic…
$JNJ 4 — Johnson & Johnson
Johnson & Johnson filed a Form 4 disclosing transactions by Jennifer L. Taubert, an executive vice president and worldwide chairman of Innovative Medicine. On August 17, 2026, s…
$JNJ 4 — Johnson & Johnson
Joaquin Duato, CEO and Chairman of the Board of Johnson & Johnson, filed a Form 4 reporting transactions in the company’s common stock on August 13, 2026. He exercised employee…